Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: A subanalysis of Japanese patients from the RENAAL study

被引：16

作者：

Kurokawa K. ^{[1
]}

Chan J.C.N. ^{[2
]}

Cooper M.E. ^{[3
]}

Keane W.F. ^{[4
]}

Shahinfar S. ^{[4
]}

Zhang Z. ^{[4
]}

机构：

[1] Research Center for Advanced Science and Technology, University of Tokyo, Meguro-ku, Tokyo 153-8904

[2] Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong

[3] Diabetes and Metabolism Division, Baker Heart Research Institute, Melbourne, Vic.

[4] Merck and Co., Inc., Whitehouse Station, NJ

来源：

Clinical and Experimental Nephrology | 2006年 / 10卷 / 3期

关键词：

Japanese patients; Losartan; Nephropathy; Proteinuria; RENAAL; Type; 2; diabetes;

D O I：

10.1007/s10157-006-0427-6

中图分类号：

学科分类号：

摘要：

Background. The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study has previously shown losartan to confer significant benefits to patients with type 2 diabetes and nephropathy. The original study of 1513 patients included 96 Japanese patients; the present study is a post-hoc analysis of the effects of losartan in this Japanese subpopulation. Methods. This double-blind, randomized study compared losartan (50 to 100 mg once daily) with placebo. The study medication was taken in addition to conventional antihypertensive treatment, and the mean follow-up period for the Japanese patients was 2.8 years. The primary endpoint was the composite of doubling of serum creatinine, endstage renal disease, or death. Secondary endpoints included changes in proteinuria levels. Safety was also evaluated. Results. The primary composite endpoint was reached in fewer Japanese patients receiving losartan than placebo (50.0% versus 65.4%, respectively). The treatment effects of losartan were more robust when data were corrected for differences in proteinuria at baseline - a significant relative risk reduction of 45% with losartan (P = 0.0397) was apparent. Treatment benefit exceeded that attributable to blood pressure changes alone. Levels of proteinuria were reduced with losartan compared with placebo, with an overall losartan treatment effect of 37.8% (P < 0.001). Overall, losartan was similarly well tolerated in both the Japanese patients and the total population. Conclusions. In Japanese patients with type 2 diabetes and nephropathy, losartan offers renal protection and is generally well tolerated. © 2006 Japanese Society of Nephrology.

引用

页码：193 / 200

页数：7

共 37 条

[1]

Wild S., Roglic G., Green A., Sicree R., King H., Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030, Diabetes Care, 27, pp. 1047-53, (2004)

[2]

Wu A.Y., Kong N.C., De Leon F.A., Pan C.Y., Tai T.Y., Yeung V.T., Et al., An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: The MicroAlbuminuria Prevalence (MAP) study, Diabetologia, 48, pp. 17-26, (2005)

[3]

Keane W.F., Kurokawa K., Lyle P.A., Shahinfar S., Smith T.P., Wieland K.K., Et al., Treatment of type 2 diabetic patients with kidney disease with AT <sub>1</sub>-receptor antagonists: Lessons from recent trials, Clin Exp Nephrol, 6, pp. 175-81, (2002)

[4]

Morrish N.J., Wang S., Stevens L.K., Fuller J.H., Keen H., Mortality and causes of death in the WHO Multinational Study of Vascular Diseases in Diabetes, Diabetologia, 44, pp. 14-21, (2001)

[5]

Usami T., Koyama K., Takeuchi O., Morozumi K., Kimura G., Regional variations in the incidence of end-stage renal failure in Japan, JAMA, 284, pp. 2622-4, (2000)

[6]

Heart O., Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy, Lancet, 355, pp. 253-9, (2000)

[7]

Lindholm L.H., Ibsen H., Dahlof B., Devereux R.B., Beevers G., De Faire U., Et al., Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol, Lancet, 359, pp. 1004-10, (2002)

[8]

Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Et al., Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, pp. 851-60, (2001)

[9]

Brenner B.M., Cooper M.E., De Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., Et al., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, pp. 861-9, (2001)

[10]

De Zeeuw D., Remuzzi G., Parving H.H., Keane W.F., Zhang Z., Shahinfar S., Et al., Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL, Kidney Int, 65, pp. 2309-20, (2004)

← 1 2 3 4 →